Scrip
Reyataz's US label revised to include long-term data for treatment-naïve HIV
06 November 2009
Katie McQue
Please Login to read the full article.
06 November 2009
Katie McQue
The US FDA has authorised Bristol-Myers Squibb to include 96-week data from the CASTLE study for previously untreated HIV infected adults in the label for its protease inhibitor Reyataz (atazanavir sulphate).
Reyataz is the most prescribed protease inhibitor in the US, where it was first...
Please Login to read the full article.
RELATED CONTENT
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
